On the stock market since 2022, it operates in the world of health and science. It has 47 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
No real growth (3% a year). Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 46% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 11% a year on average.
There is $733.5M in the vault; even if every debt were paid off, $277.8M would remain.
The stock sits at $0.0019. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, LGNDZ sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: LGNDZ is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.